No headlines found.
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
Globe Newswire (Thu, 26-Feb 4:15 PM ET)
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
BGM Group Ltd. - Class A trades on the NASDAQ stock market under the symbol BGM.
As of March 19, 2026, BGM stock price climbed to $0.91 with 66,426 million shares trading.
BGM has a beta of 0.73, meaning it tends to be less sensitive to market movements. BGM has a correlation of 0.01 to the broad based SPY ETF.
BGM has a market cap of $182.11 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that BGM belongs to (by Net Assets): PGJ, EWX, ONEQ, GXC.
BGM has underperformed the market in the last year with a price return of -91.0% while the SPY ETF gained +17.6%. BGM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -79.2% and -11.0%, respectively, while the SPY returned -3.1% and -3.2%, respectively.
BGM support price is $.81 and resistance is $.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGM shares will trade within this expected range on the day.
